Your shopping cart is currently empty

Didanosine (ddI) is a nucleoside reverse transcriptase inhibitor analog of adenosine (IC50: 0.49 μM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | $33 | In Stock | In Stock | |
| 25 mg | $51 | In Stock | In Stock | |
| 50 mg | $68 | In Stock | In Stock | |
| 100 mg | $101 | In Stock | In Stock | |
| 500 mg | $253 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $37 | In Stock | In Stock |
| Description | Didanosine (ddI) is a nucleoside reverse transcriptase inhibitor analog of adenosine (IC50: 0.49 μM). |
| Targets&IC50 | Reverse transcriptase:0.49 μM |
| In vivo | In cultured human muscle cells, Didanosine induced accumulation of cytoplasmic lipid droplets, increased lactate production, and decreased SDH (part of complex II) and COX (complex IV) activity. In HIV target cells, Didanosine was converted to its active form, deoxyadenosine-5'-triphosphate (ddATP). In dissociated DRG cells in culture, Didanosine dose-dependently induced reductions in the number of neurites, the length of each neurite in the longest neurite, and the total length of the neurite. In dissociated DRG neurons, Didanosine dose-dependently induced neurite retraction or axon loss, suggesting that desipramine is useful in the development of peripheral neuropathy. In cultured human TK6 lymphoblastoid cells, Didanosine induced mutagenicity of the thymidine kinase gene induced by zidovudine. |
| Synonyms | ddI, 2',3'-Dideoxyinosine |
| Molecular Weight | 236.23 |
| Formula | C10H12N4O3 |
| Cas No. | 69655-05-6 |
| Smiles | O=C1C2=C(N(C=N2)[C@@H]3O[C@H](CO)CC3)NC=N1 |
| Relative Density. | 1.2917 g/cm3 (Estimated) |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: < 1 mg/mL (insoluble or slightly soluble) DMSO: 70 mg/mL (296.32 mM), Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (8.47 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.